Quantitative monitoring of BCR-ABL transcript suggestion of a simplified approach considering inaccuracy of measurement and calibration

被引:1
|
作者
Röthlisberger, B
Herklotz, R
Hergersberg, M
Stricker, C
Bargetzi, M
Huber, AR [1 ]
机构
[1] Cantonal Hosp Aarau, Ctr Lab Med, CH-5000 Aarau, Switzerland
[2] Appl Genet Network, Altendorf, Switzerland
[3] Cantonal Hosp Aarau, Dept Hematol Oncol, Aarau, Switzerland
关键词
BCR-ABL; leukemia molecular monitoring; real time quantitative RT-PCR (RQ-PCR); CML;
D O I
10.1080/10428190310001625845
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
According to standard-protocols, real time quantitative RT-PCR (RQ-PCR) for quantification of BCR-ABL fusion transcripts in CML patients is performed with the construction of a standard curve for each run, each sample is analyzed at least in duplicate and 10-40 ml peripheral blood are processed. This approach is appropriate for a research laboratory, but is not suitable for a routine laboratory setting. We show that the calibration curve based on the common 5 dilution standards (between 10 and 10(6) Copies) is strongly influenced by the large variability of the measurements below 100 copies of the gene. In other words, including a standard with 10 copies is a source of error, which cannot be reduced through the construction of a standard curve with each run. Adding additional dilutions between 10 and 100 copies to the standard curve, the variance of the obtained curve is much reduced. As a conclusion, it is unnecessary to construct a calibration curve with each run since only negligible inaccuracy of calibration is added to the inaccuracy of measurement. Running of the samples in duplicate seems unnecessary since the inaccuracy of the method can be correctly estimated. Finally, we propose a standardized collection and isolation of total RNA from only 2.5 ml blood using an integrated system, which allows RNA stabilization for up to 5 days and provides snapshots of BCR-ABL fusion transcripts with higher accuracy than with non-stabilized blood samples.
引用
收藏
页码:1119 / 1121
页数:3
相关论文
共 50 条
  • [22] Development of Xpert® BCR-ABL Ultra, an Automated and Standardized Multiplex Assay with Required Performance Characteristics for BCR-ABL1 Quantitative Measurement on an International Reporting Scale
    Day, Gwo-Jen
    Lockwood, Christina
    Payton, Jacqueline E.
    Uy, Geoffrey L.
    Schiffer, Charles
    Feldman, Gerald
    Bossler, Aaron
    Woolworth, Julie
    Mims, Alice S.
    Levitas, Alba
    Shridhar, Krupa
    Huang, Sandy
    Xiao, Vivian
    Wu, Natalie
    Bates, Michael P.
    Wong, Wendy
    BLOOD, 2015, 126 (23)
  • [23] Selecting and deselecting imatinib-resistant clones:: observations made by longitudinal, quantitative monitoring of mutated BCR-ABL
    Gruber, FXE
    Lamark, T
    Ånonli, A
    Sovershaev, MA
    Olsen, M
    Gedde-Dahl, T
    Hjort-Hansen, H
    Skogen, B
    LEUKEMIA, 2005, 19 (12) : 2159 - 2165
  • [24] Selecting and deselecting imatinib-resistant clones: observations made by longitudinal, quantitative monitoring of mutated BCR-ABL
    F X E Gruber
    T Lamark
    A Ånonli
    M A Sovershaev
    M Olsen
    T Gedde-Dahl
    H Hjort-Hansen
    B Skogen
    Leukemia, 2005, 19 : 2159 - 2165
  • [25] Evaluation of Cepheid Xpert BCR-ABL Monitor Assay in Three Italian Reference Centers for Monitoring of BCRABL Transcript Levels in CML Patients
    Bochicchio, Maria Teresa
    Izzo, Barbara
    Gottardi, Enrico
    De Angelis, Biagio
    Lorenzatti, Roberta
    Venturi, Claudia
    Crasto, Francesca
    De Benedittis, Caterina
    Daraio, Filomena
    Ottaviani, Emanuela
    Volpengo, Alessandro
    Saglio, Giuseppe
    Pane, Fabrizio
    Martinelli, Giovanni
    BLOOD, 2014, 124 (21)
  • [26] THE REFERENCE STANDARD FOR BCR-ABL TRANSCRIPT MONITORING IS IMPORTANT TO DEFINE CMR IN CML PATIENTS AND TO TEST THE RQ-PCR METHOD PERFORMANCES
    Talmaci, R.
    Vulpe, A.
    Dragomir, M.
    Mueller, M.
    Cross, N.
    Coriu, D.
    HAEMATOLOGICA, 2013, 98 : 293 - 293
  • [27] Analytical performance characteristics of a quantitative RT-PCR assay of BCR-ABL for monitoring minimal residual disease in CML
    England, TE
    Wong, P
    Delaney, C
    Fesseha, G
    CLINICAL CHEMISTRY, 2005, 51 : A183 - A183
  • [28] Quantitative monitoring of BCR-ABL mRNA harboring the T315I mutation in chronic myeloid leukemia (CML)
    Chomel, Jean-Claude
    Sorel, Nathalie
    Guilhot, Francois
    Turhan, Ali G.
    BLOOD, 2007, 110 (11) : 858A - 858A
  • [29] Detection of BCR-ABL transcript by quantitative real-time PCR and Amp-CML (Transcript mediated amplification) during imatinib therapy for chronic myeloid leukemia.
    Miyamura, Koichi
    Yagasaki, Fumiharu
    Kyo, Taiichi
    Ohnishi, Kazunori
    Naoe, Tomoki
    Takeuchi, Hitoshi
    Nishimura, Miki
    Fujiwara, Shin
    Tauchi, Tetsuzo
    Ohno, Ryuzo
    BLOOD, 2006, 108 (11) : 282B - 282B
  • [30] Quantitative molecular monitoring of BCR-ABL and MDR1 transcripts in patients with chronic myeloid leukemia during imatinib treatment
    Galimberti, S
    Cervetti, G
    Guerrini, F
    Testi, R
    Pacini, S
    Fazzi, R
    Simi, P
    Petrini, M
    CANCER GENETICS AND CYTOGENETICS, 2005, 162 (01) : 57 - 62